Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
No abstract is available for this record.
Bibliographic context
Authors
Joseph M. RootmanMaggie KiragaPamela KryskowKalin HarveyPaul StametsEesmyal Santos-BraultKim P.C. KuypersZach Walsh
Watch author
Topics and keywords
psilocybin DepressionMicrodosingObservational StudyToxicity Observational Study PsilocybinMoodMental healthPsychiatryHallucinogenPsychologyMedicinePsychomotor learningClinical psychologyMajor depressive disorderPsychotomimeticBipolar disorderProfile of mood statesAnhedoniaObservational studyDepression (economics)ImipramineMood disordersAugmentMania
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trialsJournal of Psychopharmacology · 2024-10-30New Paradigms of Old Psychedelics in Schizophrenia.Unknown journal · 2022-05-22The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.Unknown journal · 2024-12-09Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review.Unknown journal · 2021-12-31